Department of Radiation Oncology, Tianjin Chest Hospital, Tianjin Cardiovascular Disease Research Institute, Tianjin 300222, PR China.
Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, PR China.
Per Med. 2021 Mar;18(2):115-127. doi: 10.2217/pme-2020-0112. Epub 2021 Feb 12.
ASF1 is involved in tumorigenesis. However, its possible role in lung adenocarcinoma (LUAD) is unclear. This study thus explored the role of and in LUAD. Data from The Cancer Genome Atlas and Gene Expression Omnibus were employed to investigate and expression and its roles in LUAD prognosis. Immunohistochemistry was applied to determine the protein expression of ASF1B of 30 LUAD patients. The upregulation of in tumor tissues is associated with worse overall survival and progress-free survival and is correlated with advanced tumor stage and tumor development. However, aberrant expression of was not found in LUAD and was not related to patients' overall survival and progress-free survival. could be a promising prognostic and therapeutic biomarker in LUAD.
ASF1 参与肿瘤发生。然而，其在肺腺癌 (LUAD) 中的可能作用尚不清楚。因此，本研究探讨了 和 在 LUAD 中的作用。 本研究使用了来自癌症基因组图谱和基因表达综合数据库的数据来研究 和 的表达及其在 LUAD 预后中的作用。应用免疫组织化学方法检测了 30 例 LUAD 患者的 ASF1B 蛋白表达。 在肿瘤组织中的上调与更差的总生存期和无进展生存期相关，并且与晚期肿瘤分期和肿瘤发展相关。然而，在 LUAD 中未发现 的异常表达，并且 与患者的总生存期和无进展生存期无关。 可能是 LUAD 有前途的预后和治疗生物标志物。
